Sign in
Not yet taking people in NetherlandsPhase 2

Testing a new PET scan tracer to stage newly diagnosed non-small cell lung cancer

Tests 68Ga-FAPI-46 PET imaging in adults newly diagnosed with non-small cell lung cancer.

Key facts

Who runs it
Academisch Ziekenhuis Maastricht
Where
Maastricht, NetherlandsSee the site
Registry title
Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study
Status
Not yet recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
2 Feb 2026
Expected to end
1 Feb 2027
Type of study
Interventional
Record updated
3 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed non-small cell lung cancer (NSCLC) proven by biopsy. It compares a new PET scan tracer (68Ga-FAPI-46) with the standard scan.

Age
18 years or older
Sex
All sexes can join
Disease stage
Biopsy-proven non-small cell lung cancer that needs, or already had, an 18F-FDG PET/CT scan as part of diagnosis
Earlier treatment
No earlier lung cancer treatment and no earlier lung surgery

Main reasons for not taking part

  • History of lung cancer (treatment) or lung surgery
  • Other cancer in the 5 years before the NSCLC diagnosis (except carcinoma in situ, melanoma in situ)
  • Chronic inflammatory disease such as rheumatoid arthritis or fibrotic lung conditions
  • Severe kidney problems (eGFR ≤30 mL/min/1.73 m²)
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Biopsy proven NSCLC needing 18F-FDG PET/CT for diagnostic workup or biopsy proven NSCLC with 18F-FDG PET/CT already performed
  • Age ≥ 18
  • ECOG score 0-2
  • Possibility to perform 68Ga-FAPI-46 PET with low dose CT within three weeks after 18F-FDG PET/CT
  • Willing and able to undergo brain MRI if not already performed or scheduled in regular care
  • Provision of signed and dated, written informed consent

Who cannot take part

  • History of lung cancer (treatment) or lung surgery
  • History of other malignancies 5 years prior to the current diagnosis of NSCLC (except carcinoma in situ, melanoma in situ)
  • Chronic inflammatory disease such as rheumatoid arthritis or fibrotic pulmonary conditions
  • Known allergy to MRI contrast agent (i.e gadolinium-based contrast agents) or CT contrast agent (iodinated contrast)
  • Patients with severe renal impairment (eGFR≤30mL/min/1.73m²; the nuclear tracer is primarily excreted through the kidneys. If a patient has severe renal impairment, clearance is reduced, leading to prolonged circulation of the nuclear tracer in the body)
  • Pregnant and lactating women
  • Brain tumor (including meningioma)
  • Contra-indication for MRI such as claustrophobia, pacemaker, clips, severe obesity

Where in Netherlands

  • Maastricht University Medical CenterMaastricht, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

The aim of this pilot study is to determine essential input parameters for an adequate sample size calculation for a subsequent diagnostic study that compares the diagnostic accuracy of standard 18F-FDG and brain MRI versus 68Ga -FAPI as PET tracer in patients with newly diagnosed NSCLC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study
Plain-language title
Testing a new PET scan tracer to stage newly diagnosed non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 February 2026